InvestorsHub Logo

bradfordbros

04/21/16 10:04 AM

#145607 RE: MXAMDUD #145603

Let's see the P results first before making any judgement calls on Prurisol's treatment abilities. In any case a successful trial will mean bringing investment dollars to CTIX a certainty whatever a topical treatment might do or not do.

tombrady12nh

04/21/16 10:06 AM

#145609 RE: MXAMDUD #145603

I'd jump ship with those 80,000 shares chalk it up to a bad investment.

I'm going to stick around see how this thing shakes out

Go CTIX

MinnieM

04/21/16 10:28 AM

#145616 RE: MXAMDUD #145603

Most people hate using messy creams and would gladly take an oral medication. Especially, one without side effects.

As others have said, let's see what the Prurisol trial results are. We get them soon. Sometime in May is soon. ;)









In Reply to 'MXAMDUD'
not good:

The Medical Letter has an article about Calcipotriene/Betamethasone foam recently approved by the FDA .(The ointment and suspension formulations have been available for many years as per the Med Letter. and the generic formulation costs about $644 for the 60 gm or 100 gram size). This is how they describe the present day treatment of mild to moderate psoriasis:
A topical steroid is usually used. Vitamin D3 analogs and the retinoid tazarotene are topical alternatives. When used alone, calcipotriene is about as effective as a medium potency steroid. The combo of calcipotriene and betamethasone is more effective and better tolerated than either component alone.
Phototherapy and systemic therapy, including biologic agents, are options for patients with moderate to severe disease.
If approved, I would doubt prurisol will command much of a price or be competitive with generic topical steroids and calcipotriene, except for cases that don't respond to first and second line treatment that might respond to prurisol